financetom
Business
financetom
/
Business
/
Zscaler Insider Sold Shares Worth $3,289,216, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Zscaler Insider Sold Shares Worth $3,289,216, According to a Recent SEC Filing
Sep 18, 2025 12:59 AM

03:45 AM EDT, 09/18/2025 (MT Newswires) -- Michael J. Rich, Chief Revenue Officer and President of Global Sales, on September 15, 2025, sold 11,718 shares in Zscaler ( ZS ) for $3,289,216. Following the Form 4 filing with the SEC, Rich has control over a total of 100,822 common shares of the company, with 100,822 shares held directly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1713683/000171368325000170/xslF345X05/wk-form4_1758158643.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Enbridge Provides 2025 Guidance; Raises Dividend by 3%
Enbridge Provides 2025 Guidance; Raises Dividend by 3%
Dec 3, 2024
07:42 AM EST, 12/03/2024 (MT Newswires) -- Enbridge ( ENB ) said Tuesday that it expects full-year 2025 adjusted earnings per share to be in a range of CA$5.50 to CA$5.90 ($3.92 to $4.20). Analysts polled by Factset expect $3.01 Enbridge ( ENB ) also said it raised its quarterly dividend by 3% to $0.9425 from $0.915 per share. The...
Top Premarket Gainers
Top Premarket Gainers
Dec 3, 2024
07:40 AM EST, 12/03/2024 (MT Newswires) -- Cheetah Net Supply Chain Service ( CTNT ) shares were up more than four-fold pre-bell Tuesday after the company said overnight it agreed to acquire labor and logistics service provider TW & EW Services. Janux Therapeutics ( JANX ) stock was 74% higher after the company said late Monday that interim data from...
BRIEF-Accord Biopharma Announces Agreement By Intas Pharmaceuticals, Ltd. To Acquire Udenyca® (Pegfilgrastim-Cbqv) Business From Coherus Biosciences, Inc., Unlocking Potential For Continued U.S. Growt
BRIEF-Accord Biopharma Announces Agreement By Intas Pharmaceuticals, Ltd. To Acquire Udenyca® (Pegfilgrastim-Cbqv) Business From Coherus Biosciences, Inc., Unlocking Potential For Continued U.S. Growt
Dec 3, 2024
Dec 3 (Reuters) - * ACCORD BIOPHARMA ANNOUNCES AGREEMENT BY INTAS PHARMACEUTICALS, LTD. TO ACQUIRE UDENYCA® (PEGFILGRASTIM-CBQV) BUSINESS FROM COHERUS BIOSCIENCES, INC., UNLOCKING POTENTIAL FOR CONTINUED U.S. GROWTH Source text: ...
Gilead Sciences Partners With Tubulis on Antibody-Drug Conjugate Development for Solid Tumors
Gilead Sciences Partners With Tubulis on Antibody-Drug Conjugate Development for Solid Tumors
Dec 3, 2024
07:45 AM EST, 12/03/2024 (MT Newswires) -- Gilead Sciences ( GILD ) said Tuesday it has entered into an exclusive option and license agreement with Tubulis to discover and develop an antibody-drug conjugate, or ADC against a solid tumor target. Gilead will receive access to Tubulis' Tubutecan and Alco5 platforms to design a Topoisomerase I inhibitor-based ADC, the company said....
Copyright 2023-2026 - www.financetom.com All Rights Reserved